The Role of Hyperuricemia in Cardiac Diseases: Evidence, Controversies, and Therapeutic Strategies.
Yue ZhengZhirui ChenJinya YangJing ZhengXiaorong ShuiYiguang YanShian HuangZheng LiangWei LeiYuan HePublished in: Biomolecules (2024)
Hyperuricemia (HUA) may lead to myocardial cell damage, thereby promoting the occurrence and adverse outcomes of heart diseases. In this review, we discuss the latest clinical research progress, and explore the impact of HUA on myocardial damage-related diseases such as myocardial infarction, arrhythmias, and heart failure. We also combined recent findings from basic research to analyze potential mechanisms linking HUA with myocardial injury. In different pathological models (such as direct action of high uric acid on myocardial cells or combined with myocardial ischemia-reperfusion model), HUA may cause damage by activating the NOD-like receptor protein 3 inflammasome-induced inflammatory response, interfering with cardiac cell energy metabolism, affecting antioxidant defense systems, and stimulating reactive oxygen species production to enhance the oxidative stress response, ultimately resulting in decreased cardiac function. Additionally, we discuss the impact of lowering uric acid intervention therapy and potential safety issues that may arise. However, as the mechanism underlying HUA-induced myocardial injury is poorly defined, further research is warranted to aid in the development novel therapeutic strategies for HUA-related cardiovascular diseases.
Keyphrases
- uric acid
- left ventricular
- heart failure
- metabolic syndrome
- oxidative stress
- inflammatory response
- diabetic rats
- cardiac resynchronization therapy
- reactive oxygen species
- single cell
- induced apoptosis
- high glucose
- cell therapy
- cardiovascular disease
- drug induced
- randomized controlled trial
- risk assessment
- atrial fibrillation
- stem cells
- endothelial cells
- binding protein
- coronary artery disease
- lps induced
- amino acid
- cell death
- congenital heart disease
- innate immune
- climate change
- cardiovascular events
- bone marrow